Cargando…
Leczyme: A New Candidate Drug for Cancer Therapy
Sialic acid-binding lectin (SBL), isolated from oocytes of Rana catesbeiana, is leczyme and has both lectin and ribonuclease (RNase) activities. A remarkable antitumor effect of SBL has also been reported. SBL agglutinates various kinds of tumor cells but not normal cells. SBL agglutination activity...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017849/ https://www.ncbi.nlm.nih.gov/pubmed/24864241 http://dx.doi.org/10.1155/2014/421415 |
_version_ | 1782480018048286720 |
---|---|
author | Tatsuta, Takeo Sugawara, Shigeki Takahashi, Kohta Ogawa, Yukiko Hosono, Masahiro Nitta, Kazuo |
author_facet | Tatsuta, Takeo Sugawara, Shigeki Takahashi, Kohta Ogawa, Yukiko Hosono, Masahiro Nitta, Kazuo |
author_sort | Tatsuta, Takeo |
collection | PubMed |
description | Sialic acid-binding lectin (SBL), isolated from oocytes of Rana catesbeiana, is leczyme and has both lectin and ribonuclease (RNase) activities. A remarkable antitumor effect of SBL has also been reported. SBL agglutinates various kinds of tumor cells but not normal cells. SBL agglutination activity is not affected by mono- or oligosaccharides. However, SBL-induced agglutination and antitumor effects are inhibited by sialomucin but not asialomucin. In addition, SBL has very little effect on sialidase-treated cells. SBL causes cancer-selective induction of apoptosis by multiple signaling pathways, which target RNA. Synergistic antitumor effects with other molecules, such as tumor necrosis factor-related apoptosis ligand (TRAIL) and interferon-γ (IFN-γ), have been reported. Thus, SBL may be a novel candidate molecule for anticancer drug development. Sialoglycoconjugates on the tumor cell surface may be associated with lectin activity and antitumor effects of SBL. We review the properties of SBL, particularly its lectin, RNase, and antitumor activities, and comprehensively examine the potential application of SBL for clinical purposes. |
format | Online Article Text |
id | pubmed-4017849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40178492014-05-26 Leczyme: A New Candidate Drug for Cancer Therapy Tatsuta, Takeo Sugawara, Shigeki Takahashi, Kohta Ogawa, Yukiko Hosono, Masahiro Nitta, Kazuo Biomed Res Int Review Article Sialic acid-binding lectin (SBL), isolated from oocytes of Rana catesbeiana, is leczyme and has both lectin and ribonuclease (RNase) activities. A remarkable antitumor effect of SBL has also been reported. SBL agglutinates various kinds of tumor cells but not normal cells. SBL agglutination activity is not affected by mono- or oligosaccharides. However, SBL-induced agglutination and antitumor effects are inhibited by sialomucin but not asialomucin. In addition, SBL has very little effect on sialidase-treated cells. SBL causes cancer-selective induction of apoptosis by multiple signaling pathways, which target RNA. Synergistic antitumor effects with other molecules, such as tumor necrosis factor-related apoptosis ligand (TRAIL) and interferon-γ (IFN-γ), have been reported. Thus, SBL may be a novel candidate molecule for anticancer drug development. Sialoglycoconjugates on the tumor cell surface may be associated with lectin activity and antitumor effects of SBL. We review the properties of SBL, particularly its lectin, RNase, and antitumor activities, and comprehensively examine the potential application of SBL for clinical purposes. Hindawi Publishing Corporation 2014 2014-04-23 /pmc/articles/PMC4017849/ /pubmed/24864241 http://dx.doi.org/10.1155/2014/421415 Text en Copyright © 2014 Takeo Tatsuta et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Tatsuta, Takeo Sugawara, Shigeki Takahashi, Kohta Ogawa, Yukiko Hosono, Masahiro Nitta, Kazuo Leczyme: A New Candidate Drug for Cancer Therapy |
title | Leczyme: A New Candidate Drug for Cancer Therapy |
title_full | Leczyme: A New Candidate Drug for Cancer Therapy |
title_fullStr | Leczyme: A New Candidate Drug for Cancer Therapy |
title_full_unstemmed | Leczyme: A New Candidate Drug for Cancer Therapy |
title_short | Leczyme: A New Candidate Drug for Cancer Therapy |
title_sort | leczyme: a new candidate drug for cancer therapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017849/ https://www.ncbi.nlm.nih.gov/pubmed/24864241 http://dx.doi.org/10.1155/2014/421415 |
work_keys_str_mv | AT tatsutatakeo leczymeanewcandidatedrugforcancertherapy AT sugawarashigeki leczymeanewcandidatedrugforcancertherapy AT takahashikohta leczymeanewcandidatedrugforcancertherapy AT ogawayukiko leczymeanewcandidatedrugforcancertherapy AT hosonomasahiro leczymeanewcandidatedrugforcancertherapy AT nittakazuo leczymeanewcandidatedrugforcancertherapy |